GlassScriptPhysician profile
Mary Esho
NPI 1598171951
$4,622.21
in general payments reported to CMS, 2019-2025
42 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $530 · 2021: $1,129 · 2022: $1,356 · 2023: $511 · 2024: $53.09 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $727.32 | 2019-2023 | |
| Abbvie INC. | $688.15 | 2019-2024 | |
| Glaxosmithkline, LLC. | $306.41 | 2019-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.15 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $232.97 | 2019-2023 | Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $225.42 | 2022 | |
| Lilly USA, LLC | $193.86 | 2019-2021 | |
| Allergan, INC. | $183.38 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.51 | 2021-2022 | |
| Abbott Laboratories | $149.24 | 2024-2025 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $141.80 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $132.70 | 2021 | |
| Amgen INC. | $128.43 | 2019-2023 | Otezla, Repatha |
| Jazz Pharmaceuticals INC. | $116.37 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $105.36 | 2019-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Esho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.